{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T22:04:55Z","timestamp":1791669895978,"version":"4.3.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T00:00:00Z","timestamp":1642982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T00:00:00Z","timestamp":1642982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100011724","name":"Muscular Dystrophy UK","doi-asserted-by":"publisher","award":["16NMDB-DB60-0004-5"],"award-info":[{"award-number":["16NMDB-DB60-0004-5"]}],"id":[{"id":"10.13039\/100011724","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>The objective\u00a0of this study is to analyse retrospective, observational, longitudinal growth (weight, height and BMI) data in ambulatory boys aged 5\u201312\u00a0years with Duchenne muscular dystrophy (DMD).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>We considered glucocorticoids (GC) use, dystrophin isoforms and amenability to exon 8, 44, 45, 51 and 53 skipping drug subgroups, and the impact of growth on loss of ambulation. We analysed 598 boys, with 2604 observations. This analysis considered patients from the UK NorthStar database (2003\u20132020) on one of five regimes: \u201cGC na\u00efve\u201d, \u201cdeflazacort daily\u201d (DD), \u201cdeflazacort intermittent\u201d (DI), \u201cprednisolone daily\u201d (PD) and \u201cprednisolone intermittent\u201d (PI). A random slope model was used to model the weight, height and BMI SD scores (using the UK90).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The daily regime subgroups had significant yearly height stunting compared to the GC na\u00efve subgroup. Notably, the average height change for the DD subgroup was 0.25 SD (95% CI \u2212\u20090.30, \u2212\u20090.21) less than reference values. Those with affected expression of Dp427, Dp140 and Dp71 isoforms were 0.77 (95% CI 0.3, 1.24) and 0.82 (95% CI 1.28, 0.36) SD shorter than those with Dp427 and\/or Dp140 expression affected respectively. Increased weight was not associated with earlier loss of ambulation, but taller boys still ambulant between the age of 10 and 11\u00a0years were more at risk of losing ambulation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>These findings may provide further guidance to clinicians when counselling and discussing GCs commencement with patients and their carers and may represent a benchmark set of data to evaluate the effects of new generations of GC.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-021-02158-9","type":"journal-article","created":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T11:03:27Z","timestamp":1643022207000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Growth pattern trajectories in boys with Duchenne muscular dystrophy"],"prefix":"10.1186","volume":"17","author":[{"given":"Georgia","family":"Stimpson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Raquq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Chesshyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Fewtrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Ridout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sarkozy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Manzur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vandana","family":"Ayyar Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramona","family":"De Amicis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Muntoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4871-6692","authenticated-orcid":false,"given":"Giovanni","family":"Baranello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the NorthStar Network","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Ambegaonkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoya","family":"Alhaswani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Baxter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Childs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabby","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"De Goede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances","family":"Gibbon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasantha","family":"Gowda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Guglieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemunu","family":"Hewawitharana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain","family":"Horrocks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imelda","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjorie","family":"Illingworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa","family":"Krishnakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anirban","family":"Majumdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Marini-Bettolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Parasuraman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sithara","family":"Ramdas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Servais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Skone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Spinty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elma","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Straub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandya","family":"Tirupathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey","family":"Willis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarod","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Wraige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayal","family":"Vijayakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Naismith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,24]]},"reference":[{"key":"2158_CR1","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1152\/physrev.00028.2001","volume":"82","author":"DJ Blake","year":"2002","unstructured":"Blake DJ, Weir A, Newey SE, Davies KE. Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol Rev. 2002;82:291\u2013329.","journal-title":"Physiol Rev"},{"issue":"5","key":"2158_CR2","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/ana.23982","volume":"74","author":"JR Mendell","year":"2013","unstructured":"Mendell JR, Rodino-Klapac LR, Sahenk Z, Roush K, Bird L, Lowes LP, et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol. 2013;74(5):637\u201347.","journal-title":"Ann Neurol"},{"issue":"2","key":"2158_CR3","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/ana.24555","volume":"79","author":"JR Mendell","year":"2016","unstructured":"Mendell JR, Goemans N, Lowes LP, Alfano LN, Berry K, Shao J, et al. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann Neurol. 2016;79(2):257\u201371.","journal-title":"Ann Neurol"},{"issue":"3","key":"2158_CR4","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/mus.27347","volume":"64","author":"KR Wagner","year":"2021","unstructured":"Wagner KR, Kuntz NL, Koenig E, East L, Upadhyay S, Han B, et al. Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: a randomized, double-blind, placebo-controlled, dose-titration trial. Muscle Nerve. 2021;64(3):285\u201392.","journal-title":"Muscle Nerve"},{"issue":"21","key":"2158_CR5","doi-asserted-by":"publisher","first-page":"e2270","DOI":"10.1212\/WNL.0000000000009233","volume":"94","author":"DE Frank","year":"2020","unstructured":"Frank DE, Schnell FJ, Akana C, El-Husayni SH, Desjardins CA, Morgan J, et al. Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy. Neurology. 2020;94(21):e2270\u201382.","journal-title":"Neurology"},{"issue":"8","key":"2158_CR6","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1001\/jamaneurol.2020.1264","volume":"77","author":"PR Clemens","year":"2020","unstructured":"Clemens PR, Rao VK, Connolly AM, Harper AD, Mah JK, Smith EC, et al. Safety, tolerability, and efficacy of viltolarsen in boys with duchenne muscular dystrophy amenable to exon 53 skipping: a phase 2 randomized clinical trial. JAMA Neurol. 2020;77(8):982\u201391.","journal-title":"JAMA Neurol"},{"issue":"4","key":"2158_CR7","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/mus.24332","volume":"50","author":"K Bushby","year":"2014","unstructured":"Bushby K, Finkel R, Wong B, Barohn R, Campbell C, Comi GP, et al. Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve. 2014;50(4):477\u201387.","journal-title":"Muscle Nerve"},{"issue":"10101","key":"2158_CR8","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/S0140-6736(17)31611-2","volume":"390","author":"CM McDonald","year":"2017","unstructured":"McDonald CM, Campbell C, Torricelli RE, Finkel RS, Flanigan KM, Goemans N, et al. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10101):1489\u201398.","journal-title":"Lancet"},{"issue":"5","key":"2158_CR9","doi-asserted-by":"publisher","first-page":"341","DOI":"10.2217\/cer-2019-0171","volume":"9","author":"E Mercuri","year":"2020","unstructured":"Mercuri E, Muntoni F, Osorio AN, Tulinius M, Buccella F, Morgenroth LP, et al. Safety and effectiveness of ataluren: comparison of results from the STRIDE Registry and CINRG DMD Natural History Study. J Comp Eff Res. 2020;9(5):341\u201360.","journal-title":"J Comp Eff Res"},{"key":"2158_CR10","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018;17:251\u201367.","journal-title":"Lancet Neurol"},{"issue":"8","key":"2158_CR11","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1097\/PHM.0b013e3181e72207","volume":"89","author":"JR Bach","year":"2010","unstructured":"Bach JR, Martinez D, Saulat B. Duchenne muscular dystrophy: the effect of glucocorticoids on ventilator use and ambulation. Am J Phys Med Rehabil. 2010;89(8):620\u20134.","journal-title":"Am J Phys Med Rehabil"},{"issue":"10","key":"2158_CR12","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.nmd.2015.07.009","volume":"25","author":"M Pane","year":"2015","unstructured":"Pane M, Fanelli L, Mazzone ES, Olivieri G, D\u2019Amico A, Messina S, et al. Benefits of glucocorticoids in non-ambulant boys\/men with Duchenne muscular dystrophy: a multicentric longitudinal study using the Performance of Upper Limb test. Neuromuscul Disord. 2015;25(10):749\u201353. https:\/\/doi.org\/10.1016\/j.nmd.2015.07.009.","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"2158_CR13","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/j.chest.2020.04.043","volume":"158","author":"F Trucco","year":"2020","unstructured":"Trucco F, Domingos JP, Tay CG, Ridout D, Maresh K, Munot P, et al. Cardiorespiratory progression over 5 years and role of corticosteroids in Duchenne muscular dystrophy: a single-site retrospective longitudinal study. Chest. 2020;158(4):1606\u201316. https:\/\/doi.org\/10.1016\/j.chest.2020.04.043.","journal-title":"Chest"},{"issue":"2","key":"2158_CR14","first-page":"149","volume":"87","author":"V Ricotti","year":"2016","unstructured":"Ricotti V, Ridout DA, Pane M, Main M, Mayhew A, Mercuri E, et al. The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials. J Neurol Neurosurg Psychiatry. 2016;87(2):149\u201355.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"2158_CR15","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1212\/WNL.0b013e318227b164","volume":"77","author":"DM Escolar","year":"2011","unstructured":"Escolar DM, Hache LP, Clemens PR, Cnaan A, McDonald CM, Viswanathan V, et al. Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Neurology. 2011;77(5):444\u201352.","journal-title":"Neurology"},{"issue":"9","key":"2158_CR16","doi-asserted-by":"publisher","first-page":"e1003222","DOI":"10.1371\/journal.pmed.1003222","volume":"17","author":"EC Smith","year":"2020","unstructured":"Smith EC, Conklin LS, Hoffman EP, Clemens PR, Mah JK, Finkel RS, et al. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: an 18-month interim analysis of a non-randomized open-label extension study. PLoS Med. 2020;17(9):e1003222. https:\/\/doi.org\/10.1371\/journal.pmed.1003222.","journal-title":"PLoS Med"},{"key":"2158_CR17","unstructured":"Leiden Open Variation Database. The DMD gene homepage. 2021. https:\/\/www.dmd.nl\/."},{"issue":"6","key":"2158_CR18","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1136\/jnnp-2012-303902","volume":"84","author":"V Ricotti","year":"2013","unstructured":"Ricotti V, Ridout DA, Scott E, Quinlivan R, Robb SA, Manzur AY, et al. Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. J Neurol Neurosurg Psychiatry. 2013;84(6):698\u2013705.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2158_CR19","doi-asserted-by":"publisher","DOI":"10.1101\/2021.07.27.21261120v1","author":"M Chesshyre","year":"2021","unstructured":"Chesshyre M, Ridout D, Hashimoto Y, Ookubo Y, Torelli S, Maresh K, et al. Duchenne muscular dystrophy patients lacking the dystrophin isoforms Dp140 and Dp71 and mouse models lacking Dp140 have a more severe motor phenotype. medRxiv. 2021. https:\/\/doi.org\/10.1101\/2021.07.27.21261120v1.","journal-title":"medRxiv"},{"issue":"3","key":"2158_CR20","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1093\/hmg\/4.3.329","volume":"4","author":"HGW Lidov","year":"1995","unstructured":"Lidov HGW, Selig S, Kunkel LM. Dp140: a novel 140 kDa CNS transcript from the dystrophin locus. Hum Mol Genet. 1995;4(3):329\u201335.","journal-title":"Hum Mol Genet"},{"issue":"4","key":"2158_CR21","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/(SICI)1097-0258(19980228)17:4<407::AID-SIM742>3.0.CO;2-L","volume":"17","author":"TJ Cole","year":"1998","unstructured":"Cole TJ, Freeman JV, Preece MA. British 1990 growth reference centiles for weight, height, body mass index and head circumference fitted by maximum penalized likelihood. Stat Med. 1998;17(4):407\u201329.","journal-title":"Stat Med"},{"key":"2158_CR22","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, Alman BA, Apkon SD, Blackwell A, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol. 2018;17:347\u201361.","journal-title":"Lancet Neurol"},{"issue":"5","key":"2158_CR23","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S1474-4422(18)30026-7","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Colvin MK, et al. Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan. Lancet Neurol. 2018;17(5):445\u201355. https:\/\/doi.org\/10.1016\/S1474-4422(18)30026-7.","journal-title":"Lancet Neurol"},{"key":"2158_CR24","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3390\/nu9060594","volume":"9","author":"S Salera","year":"2017","unstructured":"Salera S, Menni F, Moggio M, Guez S, Sciacco M, Esposito S. Nutritional challenges in duchenne muscular dystrophy. Nutrients. 2017;9:594.","journal-title":"Nutrients"},{"issue":"1","key":"2158_CR25","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejpn.2013.08.008","volume":"18","author":"E Sarrazin","year":"2014","unstructured":"Sarrazin E, Von Der Hagen M, Schara U, Von Au K, Kaindl AM. Growth and psychomotor development of patients with Duchenne muscular dystrophy. Eur J Paediatr Neurol. 2014;18(1):38\u201344. https:\/\/doi.org\/10.1016\/j.ejpn.2013.08.008.","journal-title":"Eur J Paediatr Neurol"},{"key":"2158_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2013.08.004","author":"NA West","year":"2013","unstructured":"West NA, Yang ML, Weitzenkamp DA, Andrews J, Meaney FJ, Oleszek J, et al. Patterns of growth in ambulatory males with duchenne muscular dystrophy. J Pediatr. 2013. https:\/\/doi.org\/10.1016\/j.jpeds.2013.08.004.","journal-title":"J Pediatr"},{"issue":"20","key":"2158_CR27","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1212\/WNL.0000000000003217","volume":"87","author":"RC Griggs","year":"2016","unstructured":"Griggs RC, Miller JP, Greenberg CR, Fehlings DL, Pestronk A, Mendell JR, et al. Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy. Neurology. 2016;87(20):2123\u201331.","journal-title":"Neurology"},{"issue":"3","key":"2158_CR28","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2217\/cer-2019-0170","volume":"9","author":"JR Marden","year":"2020","unstructured":"Marden JR, Freimark J, Yao Z, Signorovitch J, Tian C, Wong BL. Real-world outcomes of long-term prednisone and deflazacort use in patients with Duchenne muscular dystrophy: experience at a single, large care center. J Comp Eff Res. 2020;9(3):177\u201389.","journal-title":"J Comp Eff Res"},{"issue":"12","key":"2158_CR29","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1212\/WNL.0000000000001950","volume":"85","author":"L Bello","year":"2015","unstructured":"Bello L, Gordish-Dressman H, Morgenroth LP, Henricson EK, Duong T, Hoffman EP, et al. Prednisone\/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study. Neurology. 2015;85(12):1048\u201355.","journal-title":"Neurology"},{"issue":"5","key":"2158_CR30","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s00431-019-03336-5","volume":"178","author":"KT Kao","year":"2019","unstructured":"Kao KT, Joseph S, Capaldi N, Brown S, Di Marco M, Dunne J, et al. Skeletal disproportion in glucocorticoid-treated boys with Duchenne muscular dystrophy. Eur J Pediatr. 2019;178(5):633\u201340.","journal-title":"Eur J Pediatr"},{"issue":"6","key":"2158_CR31","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1001\/jamaneurol.2019.0242","volume":"76","author":"S Joseph","year":"2019","unstructured":"Joseph S, Wang C, Bushby K, Guglieri M, Horrocks I, Straub V, et al. Fractures and linear growth in a nationwide cohort of boys with duchenne muscular dystrophy with and without glucocorticoid treatment: Results from the uk northstar database. JAMA Neurol. 2019;76(6):701\u20139.","journal-title":"JAMA Neurol"},{"issue":"11","key":"2158_CR32","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.nmd.2017.06.007","volume":"27","author":"M Matsumoto","year":"2017","unstructured":"Matsumoto M, Awano H, Lee T, Takeshima Y, Matsuo M, Iijima K. Patients with Duchenne muscular dystrophy are significantly shorter than those with Becker muscular dystrophy, with the higher incidence of short stature in Dp71 mutated subgroup. Neuromuscul Disord. 2017;27(11):1023\u20138. https:\/\/doi.org\/10.1016\/j.nmd.2017.06.007.","journal-title":"Neuromuscul Disord"},{"issue":"8","key":"2158_CR33","doi-asserted-by":"publisher","first-page":"23504","DOI":"10.1371\/journal.pone.0023504","volume":"6","author":"M Villarreal-Silva","year":"2011","unstructured":"Villarreal-Silva M, Centeno-Cruz F, Su\u00e1rez-S\u00e1nchez R, Garrido E, Cisneros B. Knockdown of Dystrophin Dp71 impairs PC12 cells cycle: localization in the spindle and cytokinesis structures implies a role for Dp71 in cell division. PLoS ONE. 2011;6(8):23504.","journal-title":"PLoS ONE"},{"issue":"3","key":"2158_CR34","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.acthis.2019.01.002","volume":"121","author":"R Benabdesselam","year":"2019","unstructured":"Benabdesselam R, Rendon A, Dorbani-Mamine L, Hardin-Pouzet H. Effect of Dp71 deficiency on the oxytocin hypothalamic axis in osmoregulation function in mice. Acta Histochem. 2019;121(3):268\u201376.","journal-title":"Acta Histochem"},{"issue":"1","key":"2158_CR35","doi-asserted-by":"publisher","first-page":"E67","DOI":"10.1152\/ajpendo.1995.268.1.E67","volume":"268","author":"Z Rifai","year":"1995","unstructured":"Rifai Z, Welle S, Moxley RT, Lorenson M, Griggs RC. Effect of prednisone on protein metabolism in Duchenne dystrophy. Am J Physiol Endocrinol Metab. 1995;268(1):E67\u201374. https:\/\/doi.org\/10.1152\/ajpendo.1995.268.1.E67.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"3","key":"2158_CR36","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/ajmg.1320240323","volume":"24","author":"M Zatz","year":"1986","unstructured":"Zatz M, Betti RT. Benign Duchenne muscular dystrophy in a patient with growth hormone deficiency: a five years follow-up. Am J Med Genet. 1986;24(3):567\u201372.","journal-title":"Am J Med Genet"},{"issue":"3","key":"2158_CR37","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1002\/ajmg.1320240322","volume":"24","author":"M Zatz","year":"1986","unstructured":"Zatz M, Betti RTB, Frota-Pessoa O. Treatment of Duchenne muscular dystrophy with growth hormone inhibitors. Am J Med Genet. 1986;24(3):549\u201366.","journal-title":"Am J Med Genet"},{"issue":"4","key":"2158_CR38","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1002\/ajmg.1320310415","volume":"31","author":"M Zatz","year":"1988","unstructured":"Zatz M, Rapaport D, Vainzof M, De Cassia Pavanello MR, Rocha JML, Betti RTB, et al. Effect of mazindol on growth hormone levels in patients with Duchenne muscular dystrophy. Am J Med Genet. 1988;31(4):821\u201333.","journal-title":"Am J Med Genet"},{"issue":"12","key":"2158_CR39","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1038\/s41430-019-0392-2","volume":"73","author":"S Bertoli","year":"2019","unstructured":"Bertoli S, Foppiani A, De Amicis R, Leone A, Mastella C, Bassano M, et al. Anthropometric measurement standardization for a multicenter nutrition survey in children with spinal muscular atrophy. Eur J Clin Nutr. 2019;73(12):1646\u20138.","journal-title":"Eur J Clin Nutr"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-02158-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-021-02158-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-02158-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T11:11:09Z","timestamp":1643022669000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-021-02158-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,24]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2158"],"URL":"https:\/\/doi.org\/10.1186\/s13023-021-02158-9","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,24]]},"assertion":[{"value":"4 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Northstar project is a natural history registered audit of the National Neuromuscular Database, where data from DMD boys has been collected since 2016, therefore, ethics approval was not required. We are now seeking ethics approval (IRAS Project ID: 242567) as it allows us to establish the network as a research project to collect. Approval has been given via the Caldicott guardian at GOSH and at the audit committee of each trust at the individual centres involved.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"GS, SR, MC, MF, DR, VAG, RDA, AS and AM have no conflict of interest. FM is supported by the NIHR Great Ormond Street Hospital Biomedical Research Centre and has received speaker and consultancy honoraria from Sarepta Therapeutics, Avexis, PTC Therapeutics, Roche and Pfizer. The views expressed in this paper are his and not necessarily those of the NHS, NIHR or the department of health. GB is PI of clinical trials Sponsored by Pfizer, NS Pharma, and Reveragen, and has received speaker and\/or consulting fees from Sarepta, PTC Therapeutics, Biogen, Novartis Gene Therapies, Inc. (AveXis), and Roche and has worked as principal investigator of SMA studies sponsored by Novartis Gene Therapies, Inc., and Roche.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20"}}